CANACCORD GENUITY GROUP INC

Canaccord Genuity’s latest research tweaks, NAV updates and market‑wide moves reveal key valuation shifts—stay ahead of APGE, AbbVie, and life‑sciences trends for smarter trading.

Canaccord Genuity’s latest analyst moves spotlight GPCR’s bullish outlook, a cautious shift on Bango, and potential upside for West African Resources amid a volatile Canadian market.

Canaccord Genuity’s aggressive new coverage and price‑target moves show how the firm is reshaping investor sentiment across biotech, tech, and energy sectors.

Canaccord Genuity’s Q3 2026 earnings double as the firm pivots to fee‑based growth, digital‑asset custody, and mining, boosting revenue 36.5% and guiding future expansion.

Canaccord Genuity’s latest moves: a sharp “Buy” on Doximity, reduced targets on Udemy, Bark, Atlassian, and a rally for EZCORP, all backed by fresh valuation insights and a watch on the Wayland litigation.

Canaccord Genuity’s 2026 outlook shows a bullish 200‑day move, targeted EV plays like Rivian and Tesla, and strategic portfolio shifts to capture growth.

Canaccord Genuity Group Inc. has demonstrated its influence in the capital markets through a series of research releases and equity upgrades, particularly in high-growth sectors such as biotech, AI, and mining, while also highlighting potential risk…

Canaccord Genuity Group Inc. is undergoing a strategic shift, with the potential sale of its British wealth unit sparking a surge in its shares and prompting a reassessment of its long-term growth prospects.

Canaccord Genuity Group Inc. has made strategic moves in the gold sector, including a ‘Buy’ rating on Gold Fields, and continues to support companies like Rhythm Pharmaceuticals, positioning itself for potential recovery and growth.

Canaccord Genuity Group Inc. made strategic adjustments to its investment strategies, reaffirmed ‘Buy’ ratings on several companies, and navigated market movements, solidifying its position in the financial services industry.